Evidence map›Paper›PMID 32768375›Full record

ArticleJournal of the American Medical Directors Association2020

Cumulative and Incremental Value of Sarcopenia Components on Predicting Adverse Outcomes.

Freddy M H Lam, Yi Su, Zhi-Hui Lu, Ruby Yu, Jason C S Leung, Timothy C Y Kwok

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Medical Directors Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Sarcopenia in glioblastoma: pick up the probe and ditch the tomography.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024
    Article
  11. Article
  12. Computed tomography cannot see "Sarcopenic Obesity".International urology and nephrology · 2024
    Article
  13. Evaluating sarcopenia in cancer patients: focus on the rectus femoris muscle.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Sarcopenia: if it looks/walks like a duck, it must be a duck.European journal of clinical nutrition · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Freddy M H LamDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong; Jockey Club Centre for Osteoporosis Care and Control, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.
Yi SuDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Zhi-Hui LuDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Ruby YuDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong; Jockey Club Institute of Ageing, The Chinese University of Hong Kong, Hong Kong.
Jason C S LeungJockey Club Centre for Osteoporosis Care and Control, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.
Timothy C Y KwokDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong; Jockey Club Centre for Osteoporosis Care and Control, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. Electronic address: tkwok@cuhk.edu.hk.
Chinese University of Hong Kong · HK

Funding

Osteoporotic fractures in Chinese men: MrOs Hong KongR01AR049439 · NIAMS · CHINESE UNIVERSITY OF HONG KONG · PI LEUNG, PING CHUNG · 2003 to 2007
$2.0M
NIAMS NIH HHS R01 AR049439
6 · The paper itself

Abstract

objectivesTo examine the incremental value of sarcopenia components, following the diagnosis algorithm of the Asian consensus, on predicting adverse outcomes.

designA prospective cohort study. SETTING AND

participantsFour thousand community-dwelling Chinese adults (2000 men) aged 65 years or older in Hong Kong (mean age = 72.5 ± 5.2).

methodsSARC-F was used as the initial predictor of 9 adverse outcomes. In step 2, muscle strength (ie, grip strength) and/or functions (ie, chair-stand, walking speed) were added on top of SARC-F. In step 3, height-, weight-, and body mass index-adjusted appendicular skeletal mass (ASM) measured by dual-energy x-ray absorptiometry (DXA) were added separately to all models formulated in step 2. The areas under the receiver operating characteristic curve (AUCs) were calculated for the models formulated in all steps. Each cumulative AUC would be compared with the AUC yielded in the previous step to evaluate the incremental prediction value.

resultsOn top of SARC-F, assessing grip strength, walking speed, or 5-time chair-stand significantly increased the AUC for most adverse outcomes. In particular, assessing both grip strength and gait speed yielded the highest AUC in most prediction models (AUC = 0.539-0.770) and significantly increased the AUC for all outcomes except for recurrent falls. With both muscle strength and function assessed, adding ASM failed to significantly increase the AUC except for 2 conditions. In the 2 conditions, however, a higher height-adjusted ASM was associated with a higher risk of having worsened physical limitations [OR 1.25, 95% confidence interval (CI) 1.12-1.40] and decline in the physical quality of life (OR 1.18, 95% CI 1.06-1.33) in women. CONCLUSIONS AND IMPLICATIONS: Assessing muscle strength and function provides additional power to predict adverse outcomes on top of SARC-F. Further assessment of muscle mass with DXA provides no extra constructive value ito bettering the prediction regardless of the adjustment parameters. Alternative technologies to measure muscle mass might be required.

Indexed as

SarcopeniaAgedFemaleGeriatric AssessmentHand StrengthHong KongHumansMaleMuscle, SkeletalProspective StudiesQuality of Lifeadverse outcomesmuscle massolder adultsSarcopeniascreening

Identifiers

PMID32768375
PMCPMC8831392
OpenAlexW3046947761

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.